Web Exclusives

Web Exclusives — December 23, 2020

As the end of this year draws near, we at Amplity Health would like to take this opportunity to thank all of you for an amazing 2020. We also share a celebration of our victories and accomplishments with everyone, while reflecting on ways to improve as we progress into the new year! The success of Amplity Medical Communications is based on the effective and vibrant relationships we have forged over the years; we simply wouldn’t be where we are without you. We are extremely grateful for the opportunity to work with, and for you!

Phase 2 Study of Nivolumab with Gemcitabine/Cisplatin or Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable BTC (BilT-01)

Biliary Tract Cancer

Web Exclusives — May 30, 2020

The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer.

Combination Immunotherapy with Ipilimumab and Nivolumab in Patients with Advanced Biliary Tract Cancer

Biliary Tract Cancer

Web Exclusives — May 30, 2020

The response rate to the combination of ipilimumab and nivolumab in patients with advanced biliary tract cancer compared favorably to clinical trials investigating single-agent anti–PD-1 therapy.

Phase 2 Study Assessing Tolerability, Efficacy, and Biomarkers for Durvalumab ± Tremelimumab and Gemcitabine/Cisplatin in Chemo-Naïve Advanced BTC

Biliary Tract Cancer

Web Exclusives — May 30, 2020

Durvalumab ± tremelimumab plus chemotherapy was well-tolerated and showed promising efficacy in chemotherapy-naïve patients with advanced biliary tract cancer.

IDH1 Mutation Detection in ctDNA and Association with Clinical Response in Patients with Advanced iCCA from Phase 3 ClarIDHy

Cholangiocarcinoma

Web Exclusives — May 30, 2020

Detection of IDH1 mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue.

Retrospective Analysis of Post Second-Line Chemotherapy Outcomes with Advanced or Metastatic CCA and FGFR2 Fusions

Cholangiocarcinoma

Web Exclusives — May 28, 2020

In a phase 2 trial of patients with cholangiocarcinoma and FGFR2 fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit.

FOENIX-CCA2: Phase 2, Open-Label, Multicenter Study of Futibatinib in Patients with iCCA Harboring FGFR2 Gene Fusions

Web Exclusives — May 28, 2020

Preliminary data are reported for a phase 2, open-label multicenter study of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Natural History of Fibroblast Growth Factor Receptor–Altered Cholangiocarcinoma

Cholangiocarcinoma

Web Exclusives — May 28, 2020

The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review.

Phase 2 Study of mFOLFOX versus mFOLFIRI in Locally Advanced or Metastatic BTC Refractory to First-Line Chemotherapy

Biliary Tract Cancer

Web Exclusives — May 28, 2020

This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.

TreeTopp: Randomized Phase 2 Study of Varlitinib plus Capecitabine versus Placebo in Second-Line Advanced or Metastatic BTC

Biliary Tract Cancer

Web Exclusives — May 28, 2020

Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer.

Web Exclusives

Subscribe Today!

I'd like to receive:

Stay In The Know

Web Exclusives

Page 3 of 4

Subscribe Today!

I'd like to receive:

Stay In The Know